667 completed. 667 Phase 2, 47 Phase 1, 47 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 667 | Completed 667 |
| Phase 1 | 47 | Completed 47 |
| Phase 3 | 47 | Completed 47 |
Follow Respiratory Hypersensitivity: new trials by email Literature Review of Respiratory Hypersensitivity trials Research Report on Respiratory Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Environmental Exposure Unit Trial in Subjects With Ragweed-induced Allergic Rhinitis INI-2004, Placebo - Allergic Rhinitis Due to Allergens, Rhinitis Allergic | Phase 2 | Completed | Inimmune Corporation | 78 | 2026-01-19 | 2026-04-29 |
| Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma Budesonide, Formoterol Fumarate, and Umeclidinium Bromide, Budesonide and Formoterol Fumarate, Placebo for CP006 Inhalation Powder - Asthma | Phase 2 | Completed | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | 150 | 2025-11-21 | 2026-09-08 |
| Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma) Rademikibart in prefilled syringe, Matching placebo in prefilled syringe - Asthma Acute | Phase 2 | Completed | Connect Biopharm LLC | 160 | 2025-08-08 | 2026-09-16 |
| A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis SHR-1819 Injection, SHR-1819 Injection Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 108 | 2025-08-06 | 2026-08-27 |
| Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis TQC2938 injection, TQC2938 Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 136 | 2025-07-31 | 2026-02-10 |
| M-Gard Particulate EW Efficacy Study on Seasonal Allergic Rhinitis M-Gard, Placebo - Allergic Rhinitis Due to Grass Pollens | Phase 2 | Completed | RDC Clinical Pty Ltd | 20 | 2025-06-27 | 2026-03-06 |
| Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge ETH47, Placebo - Asthma (Diagnosis) | Phase 2 | Completed | Ethris GmbH | 50 | 2025-06-24 | 2026-11-03 |
| iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B) - Pulmonary Aspergillosis, Chronic Pulmonary Aspergillosis | Phase 2 | Completed | Radboud University Medical Center | 10 | 2025-05-01 | 2026-08-18 |
| A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001 CHF 6001 - Asthma | Phase 2 | Completed | Chiesi Farmaceutici S.p.A. | 50 | 2025-03-28 | 2025-11-26 |
| A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis Pumecitinib Nasal Spray 0.3%, Pumecitinib Nasal Spray 0.6%, Placebo (twice daily) - Seasonal Allergic Rhinitis | Phase 2 | Completed | Prime Gene Therapeutics Co., Ltd. | 179 | 2025-03-12 | 2026-09-09 |
| Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis TQH2722 injection, TQH2722 Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 169 | 2025-03-10 | 2025-08-12 |
| Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults JT002 Nasal spray, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Shanghai JunTop Biosciences Co., LTD | 370 | 2025-02-24 | 2025-06-11 |
| A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI - Asthma | Phase 2 | Completed | AstraZeneca | 118 | 2025-02-10 | 2026-08-27 |
| A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis. GNR-127, 20 mcg, GNR-127, 40 mcg, GNR-127, 80 mcg - Rhinitis, Allergic, Seasonal | Phase 1 / Phase 2 | Completed | AO GENERIUM | 150 | 2024-10-07 | 2026-09-21 |
| A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations AZD8630, Placebo, Inhaler - Asthma | Phase 2 | Completed | AstraZeneca | 537 | 2024-08-30 | 2026-03-02 |
| Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma AZD4604, Placebo to AZD4604 - Asthma | Phase 2 | Completed | AstraZeneca | 36 | 2024-08-05 | 2025-10-23 |
| A Study to Evaluate Solriktug in Adult Participants With Asthma NSI-8226, Placebo - Asthma | Phase 2 | Completed | Uniquity One (UNI) | 145 | 2024-07-26 | 2026-10-28 |
| A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) Verekitug (UPB-101), Placebo - Severe Asthma | Phase 2 | Completed | Upstream Bio Inc. | 479 | 2024-02-27 | 2026-05-01 |
| Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA AZD4604, Placebo - Asthma | Phase 2 | Completed | AstraZeneca | 339 | 2023-11-16 | 2025-11-13 |
| Azelastine Allergen Chamber - Onset of Action Study Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair), Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray, Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray - Seasonal Allergic Rhinitis | Phase 2 | Completed | MEDA Pharma GmbH & Co. KG | 84 | 2023-10-30 | 2024-03-20 |
Showing 20 of 667. Sign in to see all of them.
Asthma (481) · Rhinitis, Allergic (95) · Rhinitis, Allergic, Seasonal (91) · Hypersensitivity (41) · Pulmonary Disease, Chronic Obstructive (22) · Rhinitis (20) · Rhinitis, Allergic, Perennial (14) · Inflammation (11) · Dust Mite Allergy (10) · Aspergillosis, Allergic Bronchopulmonary (9) · Lung Diseases (9) · Obesity (9) · Respiratory Sounds (9) · Respiratory Tract Diseases (9) · Conjunctivitis, Allergic (7)
Hypersensitivity, Immediate (663) · Immune System Diseases (663) · Respiratory Tract Diseases (658) · Hypersensitivity (626) · Bronchial Diseases (485) · Lung Diseases (483) · Lung Diseases, Obstructive (478) · Nose Diseases (191) · Otorhinolaryngologic Diseases (191) · Rhinitis (169) · Rhinitis, Allergic (89) · Pathological Conditions, Signs and Symptoms (77) · Pathologic Processes (44) · Infections (42)
Fluticasone (29) · Formoterol Fumarate (26) · Albuterol (25) · montelukast (23) · Budesonide (17) · Mometasone Furoate (16) · Beclomethasone (14) · Omalizumab (10) · Salmeterol Xinafoate (10) · fluticasone furoate (10) · Tiotropium Bromide (9) · indacaterol (9) · 6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide (8) · Fluticasone-Salmeterol Drug Combination (8) · Cetirizine (7)
GlaxoSmithKline (64) · AstraZeneca (33) · Novartis Pharmaceuticals (30) · Chiesi Farmaceutici S.p.A. (22) · Boehringer Ingelheim (20) · Novartis (12) · Merck Sharp & Dohme LLC (11) · Genentech, Inc. (10) · MedImmune LLC (9) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · Teva Branded Pharmaceutical Products R&D, Inc. (9) · Amphastar Pharmaceuticals, Inc. (8) · Organon and Co (8) · Pfizer (8) · Sanofi (8)
United States (271) · Germany (130) · United Kingdom (111) · Canada (98) · Poland (74) · Bulgaria (41) · Russia (41) · France (39) · Hungary (37) · Ukraine (36) · South Africa (35) · Belgium (33) · Sweden (32) · Argentina (30) · South Korea (29)
Dave Singh, MD (8) · Paul O'Byrne, MD (4) · Elliot Israel, MD (3)
PMID 27881132, PMID 36472162, PMID 39393433, PMID 19001265, PMID 19748656, PMID 24010736, PMID 24184147, PMID 26001563, PMID 26283085, PMID 26704701, PMID 28758192, PMID 29656145, PMID 33217063, PMID 33305842, PMID 34089147, PMID 34379802, PMID 36253275, PMID 39035788, PMID 11398072, PMID 14619332, PMID 16387596, PMID 17021320, PMID 17631952, PMID 17950857, PMID 18244953, PMID 18403223, PMID 18566548, PMID 18699936, PMID 18787222, PMID 18946234, PMID 19136369, PMID 19196814, PMID 19264687, PMID 19614621, PMID 19656525, PMID 19680119, PMID 19728196, PMID 19821718, PMID 19943178, PMID 20001651, PMID 20012982, PMID 20056900, PMID 20100026, PMID 20110554, PMID 20193079, PMID 20334686, PMID 20412135, PMID 20528605, PMID 20545703, PMID 20920778
2009 (14), 2015 (8), 2014 (7), 2008 (6), 2016 (6), 2019 (4), 2023 (4), 2017 (3), P01HL158507 (2), 2004 (1), 2005 (1), 2018 (1), P50AT002782 (1), R01ES025124 (1), R01HL080073 (1)